|Market Maker Surveillance Report. MVIS, NKTR, OSIR, CLACW, BLPH, CTMX, Winning Stocks With Lowest Price Friction For Monday, March 20th 2017|
|[ Release Date: 03/20/2017 18:45 PDT ]
March 20, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5546 companies with "abnormal" market making, 2577 companies with positive Friction Factors and 3312 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Microvision Inc. (NASDAQ:MVIS), Nektar Therapeutics (NASDAQ:NKTR), Osiris Therapeutics Inc. (PINK:OSIR), Capitol Acquisition Corp. III (NASDAQ:CLACW), Bellerophon Therapeutics (NASDAQ:BLPH), CytomX Therapeutics Inc. (NASDAQ:CTMX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction
MVIS $0.480 0.23% 3,363,882 39.87% 3,143,043 37.25% 220,839 4,601
NKTR $6.610 0.43% 6,045,025 39.51% 5,966,902 39.00% 78,123 118
OSIR $0.540 0.17% 207,220 48.85% 162,042 38.20% 45,178 837
CLACW $0.400 0.40% 1,124,976 65.29% 337,529 19.59% 787,447 19,686
BLPH $0.270 0.26% 3,278,992 41.43% 3,017,555 38.12% 261,437 9,683
CTMX $3.670 0.24% 845,520 36.36% 820,006 35.26% 25,514 70
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows MVIS with a dollar gain Monday of $0.48000 and a Friction Factor of 4,601 shares. That means that it only took 4,601 more shares of buying than selling to move MVIS higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
Microvision Inc. (NASDAQ:MVIS) - MicroVision, Inc. develops PicoP scanning technology that can be used by its customers to create miniature projection and three-dimensional sensing and image capture solutions in the United States. Its PicoP display technology includes a two-dimensional micro-electrical mechanical systems, lasers, optics, and electronics to create a small form factor scanning engine that projects video and still image and/or uses depth sensing to capture three-dimensional data. The company offers its products primarily to original design manufacturers and original equipment manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington..
Nektar Therapeutics (NASDAQ:NKTR) - Nektar Therapeutics develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358, to treat autoimmune diseases. The company s drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California..
Osiris Therapeutics Inc. (PINK:OSIR) - Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland..
Capitol Acquisition Corp. III (NASDAQ:CLACW) - .
Bellerophon Therapeutics (NASDAQ:BLPH) - .
CytomX Therapeutics Inc. (NASDAQ:CTMX) - .
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation - Tracks all known valuation models and applies them.
GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan - Automates tracking of every technical pattern and predicts next move in stocks.
Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Content Managed by News-Articles.NET